TROY RESOURCES LTD. ORDINARY SHARES AUS (OTCMKTS:TRYRF) had an increase of 155.17% in short interest. TRYRF’s SI was 7,400 shares in March as released by FINRA. Its up 155.17% from 2,900 shares previously. With 3,000 avg volume, 3 days are for TROY RESOURCES LTD. ORDINARY SHARES AUS (OTCMKTS:TRYRF)’s short sellers to cover TRYRF’s short positions. It closed at $0.065 lastly. It is down 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The stock of Auris Medical Holding AG (NASDAQ:EARS) hit a new 52-week low and has $1.43 target or 7.00% below today’s $1.54 share price. The 9 months bearish chart indicates high risk for the $93.90M company. The 1-year low was reported on Mar, 14 by Barchart.com. If the $1.43 price target is reached, the company will be worth $6.57M less. The stock decreased 39.09% or $0.985 during the last trading session, reaching $1.535. About 621,917 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 79.78% since March 14, 2017 and is downtrending. It has underperformed by 96.48% the S&P500.
Troy Resources Limited, together with its subsidiaries, engages in the exploration and production of gold and silver properties in South America and Canada. The company has market cap of $31.03 million. The firm holds interests in the Karouni gold project located in Guyana. It currently has negative earnings.
Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Tuesday, March 15 report. The firm has “Buy” rating given on Friday, August 19 by Needham. The firm has “Buy” rating given on Friday, June 30 by Roth Capital.
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company has market cap of $93.90 million. The Company’s product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. It currently has negative earnings. The firm is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123.